CARsgen Therapeutics Company
CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor
Technology:
CAR-T, CAR-T therapy
Industry:
CAR-T, Private
Headquarters:
Shanghai, Shanghai, China
Founded Date:
2014-11-01
Employees Number:
501-1000
Funding Status:
Late Stage Venture
Investors Number:
11
Total Funding:
276000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2020-11-02
Last Funding Type:
Series C
Register and Claim Ownership